BIOTRON LIMITED — Capital/Financing Update 2026

Jan 29, 2026

==> picture [227 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: mmora@miscorp.com.au Website: www.biotron.com.au

30 January 2026

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

Dear Sir / Madam

Successful Issue of the Entitlement Offer Shortfall

Biotron Limited (ASX: BIT) ( Biotron or the Company ) is pleased to announce that the nonrenounceable rights issue first announced on 15 October 2025 has closed fully subscribed with the allotment of the shortfall under the Rights Issue now completed.

An appendix 2A for the issue of 292,666,664 fully paid ordinary shares and 146,333,324 listed options (BITO) and a supplementary prospectus accompany this announcement.

Michelle Miller, Biotron’s Managing Director, said “We are pleased that the rights issue has closed with the shortfall fully allocated, raising a further $878,000 which brings the total raised under the issue to $1,523,862 (before costs). This is in addition to the $1 million placement that completed in late 2025. With the acquisition of Sedarex Limited complete, and solid support from new and existing shareholders, the Company is now well positioned to advance its exciting diversified portfolio.”

This announcement has been authorised for release to the market by the Board of Directors.

Yours sincerely

==> picture [104 x 54] intentionally omitted <==

Marcelo Mora Company Secretary

pjn12848

Enquiries:

Dr Michelle Miller Managing Director Biotron Limited +61 (02) 9300 3344